Clinical trial
Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active…
NCT00101946 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00101946 |
|---|---|
| Title | Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Crohn's Disease |
| Intervention type | Drug |
| Interventions | 683699 |
| Enrollment | 17 |
| Start date | Oct 1, 2004 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Jan 19, 2005 |
| Last update posted | Apr 13, 2015 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: